Research Article
Antineutrophil Cytoplasmic Antibody Frequency in Chronic Hepatitis B Patients
Table 2
Comparison of the two groups by P-ANCA, C-ANCA, MPO-ANCA, and PR3-ANCA.
| | Control (, %) | CHB (, %) | |
| P-ANCA | | | | Negative | 80 (92%) | 78 (89.7%) | — | Positive | 6 (6.9%) | 3 (3.4%) | 0.4 | Borderline positive | 1 (1.1%) | 6 (6.9%) | 0.1 | All positive (any positivity) | 7 (8%) | 9 (10.3%) | 0.6 | C-ANCA | | | | Negative | 78 (89.7%) | 71 (81.6%) | — | Positive | 7 (8%) | 5 (5.7%) | 0.5 | Borderline positive | 2 (2.3%) | 11 (12.6%) | 0.009 | All positive (any positivity) | 9 (10.3%) | 16 (18.4%) | 0.1 | MPO-ANCA | | | | Negative | 78 (89.7%) | 80 (92%) | — | Positive | 5 (5.7%) | 2 (2.3%) | 0.4 | Borderline positive | 4 (4.6%) | 5 (5.7%) | 1 | All positive (any positivity) | 9 (10.3%) | 7 (8%) | 0.6 | PR3-ANCA | | | | Negative | 81 (93.1%) | 68 (78.2%) | — | Positive | 1 (1.1%) | 7 (8%) | 0.06 | Borderline positive | 5 (5.7%) | 12 (13.8%) |
0.07 | All positive (any positivity) | 6 (6.9%) | 19 (21.8%) | 0.005 |
|
|
CHB: chronic hepatitis B; ANCA: antineutrophil cytoplasmic antibody; P: perinuclear; C: cytoplasmic; MPO: myeloperoxidase; and PR3: proteinase 3.
|